Download presentation
Presentation is loading. Please wait.
1
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer: the TRAIN-2 study (BOOG ) Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
2
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Background Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
3
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Aim Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
4
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
TRAIN-2 study design Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
5
Statistical considerations
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
6
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Patient disposition Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
7
Baseline characteristics
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
8
Primary endpoint: pCR breast & axilla
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
9
pCR by hormone receptor status
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
10
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Subgroup analysis Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
11
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Treatment exposure Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
12
Grade ≥3 hematological adverse events
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
13
Grade ≥3 non-hematological adverse events
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
14
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Cardiac safety Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
15
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Discussion Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
16
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Conclusions Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
17
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Acknowledgements Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Similar presentations
